July 25, 2016 4:50pm
… As shares saunter up and down the “trading” hills
The facts and negativity of “our” universe are hard to accept as the trajectory path of advance/decline lines fluctuate
My pre-open indications – 3 hit (IMUC, CLLS and XON) and 2 miss (ADRO and JUNO)
I answer one question; in which company should investors put, keep and commit their money!
Do you care what happened today, you should … because it has implications to Tuesday's sector activity? Where has today’s market gone – subscribe and find out.
There are two things that investors need - interpretation of news and translation of market metrics concerning the stem, cell, gene and regenerative therapy sector to substantiate share pricing.
U.S. stocks closed lower in light volume trade Monday while the S&P 500 and NASDAQ were also off.
The NASDAQ closed DOWN -2.53 or -0.05% to 5,097.63 and the DOW closed DOWN -77.79 or -0.42% to 18,493.06.
A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:
- The open was negative with an A/DL of 27/13 and 3 flats;
- The mid-day flipped positive with an A/DL of 11/29 and 3 flats;
- 1:30 pm was neutral with an A/DL of 20/20 and 3 flats;
- The closing bell was negative with A/DL of 15/25 and 3 flats;
Henry’omics:
The stem, cell, gene and regenerative therapy (SCGT&RT) sector opened negative, slipped positive at the mid-day, flipped neutral at 1:30 pm and closed negative.
- As I had stated the stem, cell, gene and regenerative therapies’ sector is a slippery slope. Markets are starting off the week in a cautious approach as traders ahead of the key risk events later in the week
Last Monday, Wednesday and Friday’s positive A/DLs had positive closes while Tuesday and Thursday reflected the overbought becoming the oversold. Could Monday be a set- up day for Tuesday or the reverse, check last week’s advance/decline metrics?
Again, it is hard to right about the downside, when I wish to report the positives of “our” universe but, if one understands the negative – the positives will be clear!
Review my fear gauge or the CBOE Volatility Index (VIX):
- Monday traded above 13;
- Friday traded near 12.17;
- Thursday traded near 12.73;
- Wednesday traded near 11.72;
- Tuesday near 12.6;
- Last, Monday traded near 12.4;
Today’s Bottom Line:
I hate to be so negative but, what I say is truthful and the metrics are right-on and validate my posts.
My pre-open indications – 3 hits and 2 miss:
- Aduro Biotech (ADRO) closed UP +$0.20 – miss;
- Cellectis SA (CLLS) closed UP +$0.04 – hit;
- Intrexon (XON) closed UP +$0.37 – hit;
- Juno Therapeutics (JUNO) closed UP +$0.19 – miss;
- ImmunoCellular Therapeutics (NYSE MKT: IMUC) closed UP +0.007 – hit;
Largest decliners:
- Capricor (CAPR) -6.11% after Friday’s -4%;
- Northwest Bio (NWBO) -4.48% after Friday’s -3.05%;
- Biostage (BSTG) -2.73%;
- Asterias Biosciences (NYSEMKT: AST) -3.36% after Friday’s +2.42%;
- Neuralstem (CUR) -2.34%
Advancers:
- Cesca Therapeutics (KOOL) +9.87%;
- Histogenics (HSGX) +6.39% after being flat on Friday;
- ReNeuron (RENE.L) +5%;
- Bellicum Pharma (BLCM) +4.69%;
- Brainstorm (BCLI) +2.08%
Flat:
- Athersys (ATHX) at $2.15;
- Opexa (OPXA) at $4.10;
- StemCells (STEM) at $0.36;
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
